Status Quo in treating colorectal cancer with traditional chinese and western medicine

Yang Yu-fei

doi:10.1007/BF02836420

Your Location：

Home >

Browse articles >

Status Quo in treating colorectal cancer with traditional chinese and western medicine

Updated：2021-08-27

- Status Quo in treating colorectal cancer with traditional chinese and western medicine
- Chinese Journal of Integrative Medicine Vol. 10, Issue 3, Pages: 238-240(2004)
- Affiliations：
  
  Oncology Department, Xiyuan Hospital, China Academy of TCM,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/BF02836420
  CLC：
- Published：2004，
Scan for full text
Yu-fei, Y. Status Quo in treating colorectal cancer with traditional chinese and western medicine., Chin. J. Integr. Med. 10, 238–240 (2004). https://doi.org/10.1007/BF02836420

Yang Yu-fei. Status Quo in treating colorectal cancer with traditional chinese and western medicine. [J]. Chinese Journal of Integrative Medicine 10(3):238-240(2004)
Yu-fei, Y. Status Quo in treating colorectal cancer with traditional chinese and western medicine., Chin. J. Integr. Med. 10, 238–240 (2004). https://doi.org/10.1007/BF02836420 DOI：

Yang Yu-fei. Status Quo in treating colorectal cancer with traditional chinese and western medicine. [J]. Chinese Journal of Integrative Medicine 10(3):238-240(2004) DOI： 10.1007/BF02836420.

摘要

Abstract

关键词

Syndrome DifferentiationVival RateMedian Survival PeriodRectosigmoid CancerTional Chinese Medicine

Keywords

Syndrome DifferentiationVival RateMedian Survival PeriodRectosigmoid CancerTional Chinese Medicine

references

Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 16–29.

Peter Boyle, J S Langman. ABC of colorectal cancer: Epidemiology. BMJ 2000)321; 805–808.

Zhao N, Yao FY, Wang SS, et al. The case control study of risk factor of of Shanxi province. Chin J Epidemiolog 1990;5: 295.

Office of National Tumor Prevention and Treatment, Center for Hygienic Statistical Information, Ministry of Health chief editor. The incidence and mortality Chinese trial cities and counties (1993–1997). Volume 2. Beijing: China Medical Science and Technology Press, 2002;12: 24.

Huang T. Status quo of CRC diagnosis and treatment and prospect. Chin J General Surg Basis Clin 2001;7(1): 44.

Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanism, management and adjuvant therapy. Br J Surg 1994;81: 7–19.

Fleischer DE. Detection and surveillance of colorectal cancer. JAMA 1989;261: 580.

Jeffrey GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002;(1): CD002200.

Chan L, Cunningham D. Adjuvant chemotherapy in colon cancer. State of the art. ASCO Educational book. 2002: 228.

Cohen MA, Minsky BD, Schilsky RL. Colon cancer in cancer: Principles and practice of oncology. 4th eition. Edition by De Vita VT, Hellman S, Rosenberg SA. 1993: 29–1005.

Charles G Moertel. Chemotherapy for colorectal cancer. NEngJ Med 1994;330:1136–1142.

Lindel K, Willet CG, Shellito PC, et al. Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. Radiother Oncol 2001;58(1): 83–87.

JY Douillard, D Cunningham, AD Roth. Irinotecan combined with fluorouracil compared with fluorouracile alone as firstline treatment for metastatic colorectal cancer: a multi-center randomized trail. Lancet 2000;355(9209): 1041–1047.

Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343: 905–914.

Tournigqad C, Louver C, Quinax E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001;20: 494.

Best L, Simmonds P, Baughan C, et al. Colorectal meta-analysis. Palliative chemotherapy for advanced or matastic colorectal cancer. Cochrane Review Collaboration. The Cochrane Library. Issue 2, 2004. Oxford ISSN 1464-780X.

Li HS, Li HH, Tang ZJ, et al. Effect of Chang’ai Kangfu decoction in treating CRC postoperational immune function. Chin J Integr Tradit West Med 2000;20(8): 580.

Xin M, Wang J, Zhou C. Clinical study on Shenqi Fuzgeng injection combined with chemotherapy in treating malignant tumor of digestive tract. Chin J Integr Tradit West Med 1998;18(11): 658–661.

Li H, Li H, Tang Z. Effect of Chang’ai Kangfu decoction on immunity in postoperational patients with large intestine cancer. Chin Integr Tradit West Med 2000;20(8): 580–582.

Cao GW, Yang WG, Du P. Observation of the effects of LAK/ IL-2 therapy combining with Lycium barbarum polysaccharide in the treatment of 75 cancer patients. Chin J Oncol 1994; 16(6): 428–431.

Liu JX. The efficacy observation of 50 CRC patients treated with TCM. J TCM 1981;12: 33.

Pan MJ, Li YH, Liu JR, et al. The efficacy observation of integrative Chinese and Western medicine approach in treating 260 middle and late stage colorectal cancer. J TCM 1996;37(4): 218.

Sun GZ, Chen CH, Song L. Summarization of treating 62 CRC patients with ICWM approach. Chin J Anorectal Dis 1985; 3 (3): 5–7.

Long H, Huang ZM. The long-term efficacy assessment of TCM in treating advanced stage CRC. Jiangxi J TCM 1996; 27(4): 32.

Zhu XD, Cai MM, Wu YB, et al. Using syndrome differentiation-typing in treating 76 cases of mid-advanced CRC patients. Jiangsu J TCM 1998;19(2): 28.

Liu JA, Zhang YH. Clinical observation in treating 154 postoperational CRC patients with ICWM approaches. J Chin Herbal Med 2000;31(5): 367–368.

Zhang FZ, Yu QS. 106 cases of CRC treated with ICWM. Chin ICWM J Surg 1997;3(4): 253.

Wang BJ, Zhou ZH, Chi JX, et al. Clinical observation of longterm effect of postoperational CRC patients with comprehensive treatment of 5-Fu plus TCM. Chin ICWM J Surg 1995; 1(5): 289–291.

Guo ZX. The effect of Fuzheng Yi’ai decoction in treating postoperational CRC patients. Chin ICWM J Surg 1999;5(1): 10.

Xiao ZQ, Luo CD. Efficacy observation of Fuyuan oral liquid in treating 50 postoperational CRC patients with chemotherapy. Liaoning J TCM 1998;(11): 516.

FULL TEXT LINK

More>

Views

361

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Approaches of toxicity-reducing and efficacy-enhancing in tumor patients treated with radio- and chemotherapy

Chinese medicine syndrome distribution of chronic hepatitis b virus carriers in immunotolerant phase

Potential of renal pathology on refining syndrome typing of Chinese medicine in IgA nephropathy

A systematic analysis of the theory and practice of syndrome differentiation

Effect of treatment based on syndrome differentiation by Chinese medicine on post-traumatic elbow arthritis

Related Author

No data

Related Institution

Guanǵanmen Hospital, China Academy of Traditional Chinese Medicine

Xiyuan Hospital, China Academy of Traditional Chinese Medicine

School of Clinical Oncology, Peking University

Oncological Department, China-Japan Friendship Hospital, Ministry of Health

Traditional Chinese Medicine & Acupuncture Department, The Third Affiliated Hospital of Sun Yet-sen University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰